Diagnosis and Treatment of Helicobacter pylori Infection
Diagnostic Methods for H. pylori
- The American College of Cardiology recommends against using serology tests as the primary diagnostic method for H. pylori infection due to their inability to distinguish between active infection and past exposure, with stool antigen tests or urea breath tests being the preferred non-invasive diagnostic methods 1, 2
- Serological tests detect anti-H. pylori IgG antibodies in serum but cannot distinguish between active infection and previous exposure, with antibody levels persisting in blood for long periods, leading to false-positive results in previously treated patients 3
- The overall accuracy of commercial ELISA serology tests averages only 78% (range 68-82%), which is inadequate for clinical use on both clinical and economic grounds 3
- Serology tests should not be used to confirm eradication after treatment as antibodies remain elevated after H. pylori elimination 2
- The Urea Breath Test (UBT) is considered the most accurate non-invasive test with excellent sensitivity (94.7-97%) and specificity (95-95.7%) 4
- The Stool Antigen Test directly detects H. pylori bacterial antigens in stool specimens with sensitivity and specificity of approximately 93%, comparable to UBT 5
- Both UBT and stool antigen tests detect active infection rather than just past exposure, making them valuable for both initial diagnosis and confirmation of eradication 5, 4
Treatment of H. pylori Infection
- The "test and treat" strategy using non-invasive tests is recommended for young (<50 years) dyspeptic patients without alarm symptoms 2, 4
- Patients should be off proton pump inhibitors for at least 7 days and antibiotics/bismuth for at least 4 weeks before confirmation testing 2
- UBT or stool antigen test is recommended for confirmation rather than serology 2, 1
Special Considerations
- Serology may be useful in large epidemiologic surveys and population screening in high-prevalence areas, studies on age at acquisition of infection, and when other tests might be falsely negative (e.g., recent use of antibiotics or PPIs) and clinical suspicion is high 3, 2
- The positive predictive value of serology tests falls dramatically in populations with low disease prevalence 2
- Endoscopy is indicated for patients with alarm symptoms (bleeding, weight loss), older patients with new-onset dyspepsia, and patients who have failed eradication therapy and need culture and antimicrobial sensitivity testing 6, 1
Indications for Helicobacter pylori Testing
Primary Indications
- The American Gastroenterological Association recommends testing for H. pylori in patients with uninvestigated dyspepsia under 50 years without alarm symptoms using a "test and treat" strategy to reduce unnecessary endoscopies 7
- Patients with alarm symptoms, including bleeding, weight loss, dysphagia, palpable mass, or malabsorption, should undergo endoscopy and invasive testing 7
Situations Requiring Endoscopy and Invasive Testing
- Older patients (≥50 years) with new-onset dyspepsia should undergo endoscopy due to increased risk of malignancy 7
- Patients who have failed eradication therapy, especially when culture and antimicrobial sensitivity testing are needed to guide subsequent treatment, should undergo endoscopy and invasive testing 7, 8
- In regions with high clarithromycin resistance, culture and susceptibility testing should be performed before first-line treatment if standard clarithromycin-containing triple therapy is being considered 8
Recommended Testing Methods
Invasive Tests
- Rapid Urease Test can provide quick results during endoscopy 7
- Histology allows visualization of bacteria and assessment of mucosal damage 7
- Culture permits antimicrobial susceptibility testing, especially valuable after treatment failure 8
- PCR can detect H. pylori and antibiotic resistance directly from biopsies 8
Important Considerations and Pitfalls
- Proton pump inhibitors (PPIs) can cause false-negative results in all tests except serology and should be discontinued at least 2 weeks before testing 8
- Test selection in special populations, such as children and pregnant women, should avoid radioactive 14C-UBT but can safely undergo 13C-UBT 9
H. pylori Testing Guidelines
Primary Indications for H. pylori Testing
- Patients with active peptic ulcer disease (gastric or duodenal ulcers) should be tested for H. pylori infection, as recommended by the European Society of Gastrointestinal Endoscopy 10
- Patients with a history of peptic ulcer disease, especially those with complications such as bleeding, should be tested for H. pylori infection, as recommended by the European Society of Gastrointestinal Endoscopy 10
- Testing is indicated in patients with gastric MALT lymphoma, as recommended by the European Society of Gastrointestinal Endoscopy 10
- Patients requiring long-term PPI therapy (>1 year) should be tested due to increased risk of atrophic gastritis, as recommended by the European Society of Gastrointestinal Endoscopy 11
- Patients with atrophic gastritis or intestinal metaplasia should be tested as these are high-risk conditions for developing gastric cancer, as recommended by the European Society of Gastrointestinal Endoscopy 12
Recommended Testing Methods
- Laboratory-based validated monoclonal stool antigen test is recommended with sensitivity and specificity of approximately 93%, as recommended by the European Society of Gastrointestinal Endoscopy 10
Important Testing Considerations
- Proton pump inhibitors (PPIs) should be stopped for at least 2 weeks before testing by culture, histology, rapid urease test, UBT, or stool test, as recommended by the European Society of Gastrointestinal Endoscopy 13
- For confirmation of eradication, testing should be performed no earlier than 4 weeks after completion of treatment, as recommended by the European Society of Gastrointestinal Endoscopy 10
- The UBT or laboratory-based validated monoclonal stool test are recommended for determining the success of eradication treatment, as recommended by the European Society of Gastrointestinal Endoscopy 10
Special Populations and Considerations
- Confirmation of H. pylori eradication is strongly recommended in complicated peptic ulcer disease, gastric ulcer, and cases of low-grade gastric MALT lymphoma, as recommended by the European Society of Gastrointestinal Endoscopy 14
- In patients with bleeding ulcers, H. pylori eradication treatment should be started at reintroduction of oral feeding, as recommended by the European Society of Gastrointestinal Endoscopy 10
- In areas with high prevalence of gastric cancer, H. pylori testing followed by endoscopy in positive patients may be appropriate, as recommended by the European Society of Gastrointestinal Endoscopy 15
Pitfalls to Avoid
- Rapid in-office serological tests have limited accuracy and should be avoided, as recommended by the European Society of Gastrointestinal Endoscopy 13
- Failure to stop PPIs before testing can lead to false-negative results in all tests except serology, as recommended by the European Society of Gastrointestinal Endoscopy 13
Diagnostic Approaches for Helicobacter pylori Infection
Limitations of Serological Testing
- Serological tests detect anti-H. pylori IgG antibodies in serum but cannot reliably differentiate between active infection and previous exposure, as antibody levels persist in blood for long periods after eradication, with an overall accuracy of commercial ELISA serology tests averaging only 78% 16, 17, 18
- Serological tests cannot be used to confirm eradication after treatment as antibodies remain elevated after H. pylori elimination, and false positive results are particularly common with serology, making it unreliable for confirming active infection 19
Preferred Non-Invasive Diagnostic Tests
- The Stool Antigen Test directly detects H. pylori bacterial antigens in stool specimens with sensitivity and specificity of approximately 93%, comparable to UBT, and is valuable for both initial diagnosis and confirmation of eradication 20, 16
- Both UBT and stool antigen tests detect active infection rather than just past exposure 16, 20
Limited Situations Where Serology May Be Useful
- Serology is the only test not affected by local changes in the stomach that could lead to a low bacterial load and false-negative results of other tests, and may be appropriate when patients have recently used antibiotics, bismuth products, or proton pump inhibitors (PPIs) 17
- In patients with gastric atrophy, gastric malignancies, or ulcer bleeding, serology may be more reliable than other non-invasive tests 17
Important Testing Considerations
- Proton pump inhibitors should be stopped for at least 2 weeks before testing by culture, histology, rapid urease test, UBT, or stool test to avoid false-negative results, and histamine-2 receptor antagonists do not affect bacterial load and can be substituted for a PPI when acid suppression is needed before testing 19, 20
- For confirmation of eradication, testing should be performed using UBT or stool antigen test at least 4 weeks after completion of treatment, and serology should not be used to confirm eradication 19
Algorithm for H. pylori Testing
- For initial diagnosis in primary care setting, the first choice is the 13C-urea breath test (UBT) or laboratory-based monoclonal stool antigen test, and if patient has recently used antibiotics or PPIs, consider validated IgG serology or wait 2 weeks after stopping these medications 16, 20, 17
- For patients requiring endoscopy, perform rapid urease test, histology, or culture during endoscopy, and consider immunohistochemical staining for H. pylori when results are equivocal 21, 19
Pitfalls to Avoid
- Rapid in-office serological tests have limited accuracy and should be avoided, and failure to stop PPIs before testing can lead to false-negative results in all tests except serology 18, 20
- Using panels of IgG, IgA, and IgM tests provides no added benefit over validated IgG tests and may include non-FDA-approved tests of unclear diagnostic value 22
H. Pylori Stool Antigen Test Diagnostic Performance
Diagnostic Accuracy
- The European Helicobacter Pylori Study Group recommends using either UBT or stool antigen testing for initial diagnosis, with the stool antigen test demonstrating sensitivity of 93.2% and specificity of 93.2% based on evaluation of 3,419 patients 23, 24, 25
- The stool antigen test has a sensitivity of 92.1% and specificity of 87.6% for post-treatment confirmation when using proper gold standards 23
- The American Gastroenterological Association and the European Helicobacter Pylori Study Group equivalent, recommends using either UBT or stool antigen testing for initial diagnosis, with the understanding that only laboratory-based monoclonal antibody tests achieve high accuracy—rapid in-office immunochromatographic tests have significantly lower accuracy and should be avoided 23, 26
Test Selection and Timing
- The European Helicobacter Pylori Study Group and other guideline societies suggest that for initial diagnosis, a validated monoclonal stool antigen test or UBT should be used in patients under 50 years without alarm symptoms, with a sensitivity of 93.2% and specificity of 93.2% 23, 26
- For post-treatment confirmation, testing should be performed at least 4 weeks after completing eradication therapy, with a sensitivity of 91.6% and specificity of 98.4% for monoclonal antibody-based stool tests 26
- Medication washout periods are essential to avoid false-negative results, with proton pump inhibitors stopped at least 2 weeks before testing and antibiotics and bismuth stopped at least 4 weeks before testing 26
Advantages and Safety
- The stool antigen test detects active infection only, unlike serology which cannot distinguish current from past infection, and is safe in all populations, including children and pregnant women 23, 27
- The test is more practical than endoscopy, avoiding procedure-related discomfort, expense, and complications, and is cost-effective, being less expensive than UBT while maintaining comparable accuracy 23, 27
Diagnosis of Helicobacter pylori Infection
Diagnostic Approach Based on Clinical Context
- The American Gastroenterological Association recommends using non-invasive tests as the first line for patients under 50 years old without alarm symptoms, reducing unnecessary endoscopies by 62% compared to immediate endoscopy 28
Invasive Tests During Endoscopy
- The European Helicobacter Study Group suggests proceeding directly to endoscopy with invasive tests in patients over 50 years old with recent onset dyspepsia or presence of alarm symptoms, such as bleeding, weight loss, or dysphagia, with a strength of evidence level of moderate 28
Diagnostic Approach for Dyspepsia
Initial Testing
- For patients under 55 years old without alarm symptoms, non-invasive H. pylori testing should be the first test, not endoscopy, as recommended by the British Society of Gastroenterology 29
- The "test and treat" strategy reduces unnecessary endoscopies by 62% compared to immediate endoscopy while maintaining equivalent safety and symptom resolution, according to the European Society of Clinical Microbiology and Infectious Diseases 30
Special Considerations
- Patients over 40 years from areas at increased risk of gastric cancer or with family history of gastro-oesophageal cancer require urgent endoscopy, as suggested by the National Institute for Health and Care Excellence 29
- Any patient with alarm symptoms (bleeding, weight loss, dysphagia, palpable mass, anemia, malabsorption) regardless of age should undergo endoscopy first, as recommended by the American Gastroenterological Association 29, 30
Management
- Provide eradication therapy immediately without requiring endoscopy in young patients without alarm symptoms, as recommended by the European Helicobacter Study Group 29
- Eradication reduces future peptic ulcer risk, complications from NSAIDs, and gastric cancer risk, according to the American College of Gastroenterology 29
Diagnostic Approach for H. pylori Infection
Non-Invasive Testing
- The European Society of Gastrointestinal Endoscopy recommends validated IgG serology should only be used in specific circumstances, such as recent antimicrobial or PPI use, ulcer bleeding, atrophic gastritis, or gastric malignancies, with a sensitivity and specificity of approximately 78% 31
Invasive Testing
- The European Society of Gastrointestinal Endoscopy suggests histology requires at least two biopsy samples from antrum and body for improved sensitivity, allowing visualization of bacteria and mucosal damage 31
- The European Society of Gastrointestinal Endoscopy recommends culture with susceptibility testing provides definitive proof and antimicrobial resistance patterns, particularly valuable in regions with high clarithromycin resistance (>15-20%) or after treatment failure 32, 33
Critical Medication Washout Periods
- The European Society of Gastrointestinal Endoscopy advises stopping PPIs for at least 2 weeks before testing by culture, histology, RUT, UBT, or stool test, as PPIs cause 10-40% false-negative rates by reducing bacterial load 31, 32, 33
H. Pylori Diagnosis and Treatment
Diagnostic Approach
- The American Gastroenterological Association recommends using the urea breath test or laboratory-based monoclonal stool antigen test as first-line diagnostic methods in patients under 50 years old with uninvestigated dyspepsia without alarm symptoms, with a sensitivity of 94-97% and specificity of 95-97.7% 34, 35
Treatment Approach
- The American College of Gastroenterology recommends bismuth quadruple therapy for 14 days, a combination of tablets with meals plus a proton pump inhibitor four times daily, as a first-line empiric treatment option when local resistance patterns support a >90% cure rate 34
- The European Helicobacter Study Group recommends rifabutin triple therapy for 14 days, consisting of rifabutin, amoxicillin, and a proton pump inhibitor, as an alternative first-line empiric treatment option 34
- The American Gastroenterological Association suggests using 20-40 mg esomeprazole or rabeprazole twice daily for optimal outcomes and avoiding pantoprazole 34, 35, 36
Treatment Outcomes
- Eradication therapy reduces future peptic ulcer risk, complications from nonsteroidal anti-inflammatory drugs, and gastric cancer risk, with a recommended wait of at least 4 weeks after completing eradication therapy before testing for confirmation 34, 35
Giemsa Staining for H. pylori Diagnosis
Introduction to Giemsa Staining
- Modified Giemsa staining is the recommended histological method for detecting H. pylori during endoscopy because it is sensitive, inexpensive, easy to perform, and reproducible, though immunohistochemistry remains the gold standard when results are equivocal 37
Indications for Giemsa Staining
- Histology with Giemsa staining should be performed for patients who have failed eradication therapy and need culture/susceptibility testing, according to the American Gastroenterological Association 38
- Giemsa staining is recommended for confirmation of healing in gastric ulcers or follow-up of dysplastic lesions, as suggested by the European Helicobacter Study Group 39
Performance and Technique of Giemsa Staining
- Modified Giemsa achieves 90-95% sensitivity when performed correctly, with a specificity ranging from 95-98% due to H. pylori's distinctive morphology and location on epithelial cell surfaces 37
- Obtaining at least two biopsy samples from both antrum and body is crucial, as single biopsies miss infections due to patchy colonization, with a strength of evidence level of high 37
Comparison with Other Staining Methods
- Immunohistochemistry is the established gold standard with highest sensitivity and specificity, but is more expensive, according to the American College of Gastroenterology 37
- Modified Giemsa, Warthin-Starry, Gimenez, and Genta stains show no clear superiority to each other in terms of cost, convenience, and sensitivity, with a strength of evidence level of moderate 37
Critical Pitfalls to Avoid
- Single antral biopsies yield positive results in only 90% of infected stomachs, highlighting the importance of taking biopsies from both antrum and body, as recommended by the American Society for Gastrointestinal Endoscopy 37
- Pathologist experience and conscientiousness significantly affect sensitivity, with formal observer agreement studies showing relatively poor concordance among pathologists even with careful examination, with a strength of evidence level of low 37
Integration with Other Diagnostic Tests
- Rapid urease test (RUT) requires 10⁴ organisms for positive results—lower bacterial densities yield false negatives, making histology necessary, according to the European Society of Gastrointestinal Endoscopy 37
- RUT sensitivity ranges only 80-95% in pretreatment patients, and has poor sensitivity and specificity for post-treatment assessment, with a strength of evidence level of moderate 37
Guidelines for Helicobacter pylori Testing and Management
Age‑Based Testing Strategy
- Patients under 40–45 years with dyspepsia and no alarm symptoms should undergo non‑invasive H. pylori testing (¹³C‑urea breath test or stool antigen test). This applies when the presentation is uncomplicated and endoscopy is not indicated. 40, 41
- Before testing without endoscopy, clinicians must exclude a family history of gastric cancer, as this risk factor mandates specialist referral. 40
A non‑invasive test‑and‑treat approach in this age group is cost‑effective and captures individuals with uncomplicated duodenal ulcer disease who benefit from eradication therapy. 40
- Patients over 45–50 years with severe dyspeptic symptoms should be referred for endoscopy with invasive H. pylori testing, because gastric cancer incidence rises markedly (≈19 cases/100 000 men and 9 cases/100 000 women in the European Community). 40
- In regions with higher gastric‑cancer prevalence, the age threshold for endoscopic referral may be lowered. 40
Alarm Symptoms Requiring Immediate Endoscopy (Any Age)
- Anemia warrants direct endoscopic evaluation. 40
- Unintentional weight loss mandates immediate endoscopy. 42
- Dysphagia (difficulty swallowing) triggers urgent endoscopic assessment. 40
- Palpable abdominal mass requires prompt endoscopy. 42
- Gastrointestinal bleeding calls for immediate endoscopic investigation. 42
- Malabsorption should lead to direct endoscopic referral. 42
Pre‑Testing Medication Management
- Proton‑pump inhibitors (PPIs) must be discontinued for at least 2 weeks before performing urea breath test, stool antigen test, rapid urease test, histology, or culture. 42
- PPIs can cause 10–40 % false‑negative results by suppressing bacterial load, especially in the antrum. 42
- Serology is the only H. pylori test unaffected by ongoing PPI therapy and can be performed without a wash‑out period. 42
Selection of Diagnostic Tests
- Rapid in‑office serological tests have suboptimal accuracy (sensitivity 63–97 %, specificity 68–92 %). They are not recommended as first‑line diagnostics. 40
- Validated IgG ELISA serology may be used only when patients cannot stop PPIs/antibiotics, or in settings of gastric atrophy, malignancy, or ulcer bleeding where bacterial load is low. 42
- Culture with antimicrobial susceptibility testing is advised in areas with high clarithromycin resistance (>15–20 %) or after treatment failure. 42
Common Pitfalls to Avoid
- Do not perform H. pylori testing on patients taking PPIs unless the medication has been stopped for ≥2 weeks or serology is used instead. 42
All statements are supported by the cited references.
Guidelines for Non‑Invasive Helicobacter pylori Testing
Medication Washout Requirements
Test Accuracy and Preferred Methods
Indications for Non‑Invasive Testing
Situations Requiring Direct Endoscopy (Avoid Non‑Invasive Tests)
Limitations of Serology
Post‑Treatment Confirmation
Common Pitfalls to Avoid
Diagnostic Testing for Active Helicobacter pylori Infection
Preferred First‑Line Tests
Test Characteristics
Urea Breath Test (13C‑UBT)
Laboratory‑Based Monoclonal Stool Antigen Test
Tests to Avoid
Medication Washout Recommendations
Practical Testing Guidance
Guidelines for Testing and Managing Helicobacter pylori Infection
Age‑Based Testing Strategy
In patients younger than 45–50 years presenting with dyspepsia and no alarm features, a non‑invasive H. pylori test (¹³C‑urea breath test or laboratory‑based monoclonal stool antigen) should be performed. This “test‑and‑treat” approach reduces unnecessary endoscopies by about 62 % while preserving safety and symptom outcomes, and it is cost‑effective for detecting uncomplicated duodenal ulcer disease. 55
Before testing younger patients, a family history of gastric cancer must be excluded; the presence of such a history mandates referral to a specialist regardless of age. 55
Patients aged 45 years or older with new‑onset or severe dyspeptic symptoms should be referred directly for endoscopy with invasive H. pylori testing. Gastric cancer incidence rises sharply in this age group (≈19 per 100 000 men and 9 per 100 000 women in the European Community). 55
In regions where gastric cancer prevalence is higher, the age threshold for endoscopic referral should be lowered to below 45 years. 55
Alarm Symptoms Requiring Immediate Endoscopy
- Any patient (any age) who exhibits alarm features should proceed straight to endoscopy rather than non‑invasive testing. Alarm features include anemia, unintentional weight loss, dysphagia, a palpable abdominal mass, gastrointestinal bleeding, and malabsorption. 55
Preferred and Non‑Preferred Testing Methods
- Rapid in‑office serological tests should not be used because of poor accuracy (sensitivity 63–97 %, specificity 68–92 %). 55
Medication Washout Requirements
Proton‑pump inhibitors must be discontinued for at least 2 weeks before performing a urea breath test, stool antigen test, rapid urease test, histology, or culture. Ongoing PPI use can cause 10–40 % false‑negative results by suppressing bacterial load. 55
Antibiotics and bismuth compounds must be stopped for at least 4 weeks before any H. pylori testing. 55